Redeye updates on Evolution post Q2-results which came in slightly lower than expected. While we trim our estimates (2022-24E EBITDA down c. 2-3%) due to slower than expected growth in Asia, we are positive to the solid growth in US and the increased share of regulated revenue.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/